Triplet induction chemotherapy followed by less invasive surgery without reconstruction for human papillomavirus-associated oropharyngeal cancers: Why is it successful or unsuccessful?
Free-flap reconstruction
HPV
Induction chemotherapy
Less invasive surgery
Oropharyngeal cancer
Pathological complete response
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
20
12
2020
accepted:
23
02
2021
pubmed:
9
3
2021
medline:
9
3
2021
entrez:
8
3
2021
Statut:
ppublish
Résumé
De-escalating treatments have been focused on for HPV-associated oropharyngeal squamous cell carcinoma (OPSCC). We assessed the efficacy of a triplet induction chemotherapy (ICT) followed by surgery with or without neck dissection (ND) for locally advanced OPSCC, aiming at less invasive surgery without free-flap reconstruction and avoiding postoperative irradiation. This was a retrospective study of 41 patients with advanced resectable HPV-positive OPSCC who underwent ICT followed by surgery of primary resection with or without ND. Patients underwent triplet ICT, including docetaxel, cisplatin, and 5-fluorouracil, or carboplatin, paclitaxel, and cetuximab. Twenty-nine patients had tonsillar cancer, 15 patients were current smokers, and 18 and 12 patients had T2N1M0 and T1N1M0 status (UICC 8th), respectively. After ICT, a surgical procedure without free-flap reconstruction and tracheostomy was possible in 90.2%. Pathological complete response at both the primary site and lymph nodes was achieved in 73.2%. Of the patients who underwent surgery, no adjuvant radiotherapy was required in 85.0%. Two patients (4.9%) experienced recurrence at regional lymph nodes, but were cured by salvage ND followed by adjuvant radiotherapy. Upfront ICT using highly responsive triplet chemotherapeutic regimens may enable us to perform less invasive surgery without free-flap reconstruction and to avoid postoperative irradiation to the locoregional field through excellent postoperative pathological features.
Sections du résumé
BACKGROUND
BACKGROUND
De-escalating treatments have been focused on for HPV-associated oropharyngeal squamous cell carcinoma (OPSCC). We assessed the efficacy of a triplet induction chemotherapy (ICT) followed by surgery with or without neck dissection (ND) for locally advanced OPSCC, aiming at less invasive surgery without free-flap reconstruction and avoiding postoperative irradiation.
METHODS
METHODS
This was a retrospective study of 41 patients with advanced resectable HPV-positive OPSCC who underwent ICT followed by surgery of primary resection with or without ND. Patients underwent triplet ICT, including docetaxel, cisplatin, and 5-fluorouracil, or carboplatin, paclitaxel, and cetuximab.
RESULTS
RESULTS
Twenty-nine patients had tonsillar cancer, 15 patients were current smokers, and 18 and 12 patients had T2N1M0 and T1N1M0 status (UICC 8th), respectively. After ICT, a surgical procedure without free-flap reconstruction and tracheostomy was possible in 90.2%. Pathological complete response at both the primary site and lymph nodes was achieved in 73.2%. Of the patients who underwent surgery, no adjuvant radiotherapy was required in 85.0%. Two patients (4.9%) experienced recurrence at regional lymph nodes, but were cured by salvage ND followed by adjuvant radiotherapy.
CONCLUSIONS
CONCLUSIONS
Upfront ICT using highly responsive triplet chemotherapeutic regimens may enable us to perform less invasive surgery without free-flap reconstruction and to avoid postoperative irradiation to the locoregional field through excellent postoperative pathological features.
Identifiants
pubmed: 33683512
doi: 10.1007/s10147-021-01894-z
pii: 10.1007/s10147-021-01894-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1039-1048Références
Jemal A, Simard EP, Dorell C et al (2013) Annual Report to the Nation on the Status of Cancer, 1975–2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 105:175–201
doi: 10.1093/jnci/djs491
Ragin C, Liu JC, Jones G et al (2017) Prevalence of HPV infection in racial-ethnic subgroups of head and neck cancer patients. Carcinogenesis 38:218–229
doi: 10.1093/carcin/bgw203
Howard J, Dwivedi RC, Masterson L et al (2018) De-intensified adjuvant (chemo)radiotherapy versus standard adjuvant chemoradiotherapy post transoral minimally invasive surgery for resectable HPV-positive oropharyngeal carcinoma. Cochrane Database Syst Rev. 12:CD012939
pubmed: 30550641
Fakhry C, Westra WH, Li S et al (2008) Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100:261–269
doi: 10.1093/jnci/djn011
Licitra L, Perrone F, Bossi P et al (2006) High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 24(36):5630–5636
doi: 10.1200/JCO.2005.04.6136
Nichols AC, Theurer J, Prisman E et al (2019) Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncol 20:1349–1359
doi: 10.1016/S1470-2045(19)30410-3
Chen AM, Felix C, Wang PC et al (2017) Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study. Lancet Oncol 18:803–811
doi: 10.1016/S1470-2045(17)30246-2
Marur S, Li S, Cmelak AJ et al (2017) E1308: phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx—ECOG-ACRIN Cancer Research Group. J Clin Oncol 35(5):490–497
doi: 10.1200/JCO.2016.68.3300
Seiwert TY, Foster CC, Blair EA et al (2019) OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann Oncol 30:297–302
doi: 10.1093/annonc/mdy522
Forastiere AA, Goepfert H, Maor M et al (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091–2098
doi: 10.1056/NEJMoa031317
Forastiere AA, Zhang Q, Weber RS et al (2013) Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 31:845–852
doi: 10.1200/JCO.2012.43.6097
Garden AS, Harris J, Trotti A et al (2008) Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: a phase II trial of the radiation therapy oncology group (RTOG 99-14). Int J Radiat Oncol Biol Phys 71:1351–1355
doi: 10.1016/j.ijrobp.2008.04.006
Machtay M, Moughan J, Trotti A et al (2008) Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 26:3582–3589
doi: 10.1200/JCO.2007.14.8841
Yokota T, Onitsuka T, Kusafuka K et al (2014) Is postoperative adjuvant chemoradiotherapy necessary for high-risk oropharyngeal squamous cell carcinoma? Int J Clin Oncol 19:38–44
doi: 10.1007/s10147-013-0532-y
Park YM, Kim HR, Cho BC et al (2017) Transoral robotic surgery-based therapy in patients with stage III–IV oropharyngeal squamous cell carcinoma. Oral Oncol 75:16–21
doi: 10.1016/j.oraloncology.2017.10.014
Amin JD, Kallen ME, Hatten KM (2020) Radical tonsillectomy and superior pharyngeal constrictor anatomy: a cadaveric and oncologic specimen assessment. ORL J Otorhinolaryngol Relat Spec 82:1–9
doi: 10.1159/000508136
Posner MR, Hershock DM, Blajman CR et al (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705–1715
doi: 10.1056/NEJMoa070956
Vermorken JB, Remenar E, van Herpen C et al (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695–1704
doi: 10.1056/NEJMoa071028
Shirasu H, Yokota T, Kawakami T et al (2020) Efficacy and feasibility of induction chemotherapy with paclitaxel, carboplatin and cetuximab for locally advanced unresectable head and neck cancer patients ineligible for combination treatment with docetaxel, cisplatin, and 5-fluorouracil. Int J Clin Oncol 25:1914–1920
doi: 10.1007/s10147-020-01742-6
Burke MS, Loree JT, Popat SR et al (2020) Presurgical induction chemotherapy for squamous cell carcinoma of the tonsil. Laryngoscope 130:1206–1211
doi: 10.1002/lary.28180
Inhestern J, Schmalenberg H, Dietz A et al (2017) A two-arm multicenter phase II trial of one cycle chemoselection split-dose docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy before two cycles of split TPF followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1). Ann Oncol 28:1917–1922
doi: 10.1093/annonc/mdx202
Sadeghi N, Khalife S, Mascarella MA et al (2020) Pathologic response to neoadjuvant chemotherapy in HPV-associated oropharynx cancer. Head Neck 42:417–425
doi: 10.1002/hed.26022
Sadeghi N, Li NW, Taheri MR et al (2016) Neoadjuvant chemotherapy and transoral surgery as a definitive treatment for oropharyngeal cancer: a feasible novel approach. Head Neck 38:1837–1846
doi: 10.1002/hed.24526
Saito Y, Hayashi R, Iida Y et al (2020) Optimization of therapeutic strategy for p16-positive oropharyngeal squamous cell carcinoma: Multi-institutional observational study based on the national Head and Neck Cancer Registry of Japan. Cancer. https://doi.org/10.1002/cncr.33062 (Epub ahead of print)
doi: 10.1002/cncr.33062
pubmed: 32907549